Posts for Ticker ‘MNKD’

Top Day Trader Alerts (GE, PALM, VVUS, OREX, ARNA, MNKD)

Here are Wednesday’s top day trader and active trader alerts with more detailed trading volume and price analysis in the links over at VSInvestor.com:

General Electric Co. (NYSE:GE) is challenging post-crash highs on an analyst upgrade.

Palm Inc. (NASDAQ: PALM) is down over 5% on an analyst downgrade.

VIVUS Inc. (NASDAQ: VVUS) is soaring by over 50% on what is already exponential volume on its key Qnexa weight loss study showing incredible weight loss results.

Perceived competitors of VIVIS to the tune of Orexigen Therapeutics Inc. (NASDAQ: OREX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and even MannKind Corp. (NASDAQ: MNKD) are all running up modestly on this news, although these are less discovered in comparison to a 50% gain.

You can join our open email distribution list which goes out several times per week if you wish to be notified by email when the top day trader alerts hit, along with news of IPO’s, key offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
SEPTEMBER 9, 2009

Posted on: September 9, 2009 – 9:27 am in After-Hours Activity, Pre-Market Activity, Trading Alert, , , , , ,

The War On Diabetes Heats Up (NVO, AMLN, LLY, MNKD, PFE, VVUS, BMY, AZN, ARNA, GERN, STEM, OREX, GNBT, SPEX, ORMP, HDIX, PODD)

Biotech ImageDiabetes is becoming an epidemic in the U.S. and the Western World.  The ties to obesity are often direct, so the potential treatments are often directly tied as well.  We did a recent dig down for the next $170 billion opportunity for eight different major diseases and conditions, and now we have conducted a much deeper dig down specifically in the field of diabetes over at BioHealthInvestor.com.  We have recent and upcoming FDA action and data being presented from Novo Nordisk (NYSE: NVO), MannKind Corp. (NASDAQ: MNKD), Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly (NYSE: LLY), Alkermes Inc. (NASDAQ: ALKS), Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN).  There is a mini-race going on between some of the later stage studies from obesity and diabetes candidates from Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), VIVUS, inc. (NASDAQ: VVUS), Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Amylin Pharmaceuticals Inc. (NASDAQ: AMLN).  Geron Corporation (NASDAQ: GERN) and StemCells Inc. (NASDAQ: STEM) were noted as two of the stem cell hopes, although stem cells may later rather than sooner.

Generex Biotechnology Corporation (NASDAQ: GNBT), Spherix Incorporated (NASDAQ: SPEX) and Oramed Pharmaceuticals Inc. (OTCBB: ORMP) were all noted in the much smaller or emerging plays.  Home Diagnostics, Inc. (NASDAQ:HDIX) and Insulet Corporation (NASDAQ: PODD) have both recently had key events as the interest in test equipment companies continues to remain high.

FULL STORY with much more detail at BioHealthInvestor.com.

Posted on: August 10, 2009 – 10:56 am in Biotech, Drug companies, FDA, Healthcare, Medical, , , , , , , , , , , , , , , , ,

Long Line of Biotech Secondary Stock Offerings (MNKD, IDIX, ISPH, ARIA, ONTY, NBY, SOMX, ARNA, OXGN)

Money Stack ImageIt seems that there is another endless line of biotech and emerging pharmaceutical companies which have raised cash or have filed to raise cash.  MannKind Corporation (NASDAQ: MNKD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) have all priced secondary offerings of common stock for close to $175 million total among all three offerings this morning alone.  Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) had its pricing yesterday of a secondary offering and Oncothyreon Inc. (Nasdaq: ONTY) announced terms for a direct offering of securities.   NovaBay Pharmaceuticals, Inc. (NYSE: NBY) filed this week for a capital raise.

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and OXiGENE, Inc. (NASDAQ: OXGN) have all filed this week with the SEC for the resale of securities by secondary offering and private placement buyers in recent weeks.

You can read the full story with details on each offering over at BioHealthInvestor.com.

And imagine this… it is only Wednesday.

-The 24/7 Wall St. Team

Posted on: August 5, 2009 – 1:28 pm in Biotech, Secondary Offering, , , , , , , , ,

MannKind Raises Over $50 Million (MNKD, PFE)

Money Stack ImageMannKind Corporation (NASDAQ: MNKD) is getting hit after the company announced that it priced a secondary offering of 7,400,000 shares of its common stock.  While the press release does not say what price the deal came at, the syndicate group told us this went out at $7.35 per share.  The company’s chairman, CEO, and principal stockholder, Alfred E. Mann, is purchasing 1,000,000 of these shares from the underwriters.
Read More »

Posted on: August 5, 2009 – 9:55 am in Biotech, Drug companies, Secondary Offering, ,

The Next Blockbuster Drugs: A $170 Billion Opportunity

biotech

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market.

With help from Thomson Pharma and our own backlog of coverage, BioHealthInvestor.com, a 247wallst.com website, sought to find the most promising biopharmaceutical candidate from both biotech and pharmaceutical companies in each of the top 10 most prevalent medical conditions in the U.S. Read More »

Posted on: July 22, 2009 – 4:01 am in Biotech, Drug companies, Editor's Picks, Pharmaceuticals, , , , , , , , , , , , , , , , , , , , ,

Biotech Business Daily (BTRX, BMRN, DSCO, ENDP, MNKD, MIPI, QSC, TECH)

Today almost feels like the "March of Biotech-inguins" because most of the movers were small companies you might otherwise miss.  Here were the big movers:

  • Barrier Therapeutics (NASDAQ: BTRX) ran way up after first quarter results reported yesterday showed a 207% increase in revenues from last year at $8.4 million, driven by growth in sales of Vusion and Xolegel. Shares closed up 18% at $2.29 on a 52-week range of $1.90 to $7.60.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) showed a first quarter positive profit or $0.02 EPS on a net income of $1.7 million. Analysts expected losses of $0.05 EPS. Earnings were driven primarily by sales of enzyme replacement therapy Naglazyme. Shares closed up almost 8% at $36.46. The 52-week range is $15.99 to $41.00.
  • Discovery Labs (NASDAQ: DSCO) trading up in anticipation of FDA approval for lung surfactant, Surfaxin, a treatment for premature infants suffering from respiratory distress. The company communicated confidence that any regulatory concerns have been ironed out and this third FDA result will be positive. Shares rose 17% to $2.87. The 52-week range is $1.75 to $3.75.
  • Endo Pharmaceuticals (NASDAQ: ENDP) settled a proxy battle with shareholder D.E. Shaw by nominating William Spangler to the board. They posted earnings today showing a net income of $59.53 and $0.44 EPS. Shares closed down 0.7% at $24.83. The 52-week range is $22.62 to $35.85.
  • Mannkind Corporation (NASDAQ: MNKD) up over 16% in anticipation of earnings release Monday. Shares up $0.37 at $2.60 at the close. The 52-week range is $1.86 to $14.71.
  • Molecular Insight Pharma (NASDAQ: MIPI) up almost 7% today on no news, although some just may be the thin volume and wide bid/ask spread. The oncology molecular imaging pharmaceutical company is sitting at $7.83 on a 52-week range of $5.66 to $12.95.
  • Questcor (AMEX: QSC) down despite posting strong first quarter results showing a positive net income of $6.5 million compared to a loss of $3.8 in first quarter 2007. The company also amended agreement Acthar distribution discount prices, positively impacting Questcor cash flows. Shares closed down 2.5% at $4.24. The 52-week range is $0.21 to $6.60.
  • Techne Corp. (NASDAQ: TECH) up after third quarter profit jumped 24% to $29.6 million or $0.76 EPS, beating estimates. Shares closed at $72.52, up 1%, on a 52-week range of $54.49 to $72.00.

Rachel Lopez
April 30, 2008

Posted on: April 30, 2008 – 3:21 pm in Biotech, Newsletter, , , , , , , ,

Biotech Busine$$ Daily (ALKS, CADX, CVTX, MNKD, GNBT, PPHM)

Alkermes (NASDAQ: ALKS) and Johnson & Johnson Pharmaceutical Research and Developed today submitted paperwork seeking approval of their partnership drug, RISPERDAL CONSTA, to be allowed for treatment of bipolar disorder chronic relapse. The drug was already approved for treatment of schizophrenia in 2003. Shares of Alkermes are down to by $0.17 to $10.94 in mid-day trading on a 52-week range of $10.32 to $18.78.

Cadence Pharmaceuticals Inc. (NASDAQ: CADX) up over 8% today on no new developments to $6.74 off a 52-week range of $4.84 to $20.67. Cadence Pharmaceuticals is a development stage biopharmaceutical company with two products in Phase III testing, Acetavance and Omigard.

CV Therapeutics (NASDAQ: CVTX) down today despite FDA approval for its coronary artery treatment, Lexiscan, granted last Friday. The drug is injected into patients during heart tests that cannot exercise to increase blood flow in their arteries. The drug will be marketed by OTC company Astellas Pharma US Inc. and will pay CV Therapeutics $12 million now that drug has been approved. CV Therapeutics is down over 5% to $7.57 on a 52-week range of $5.41 to $13.74.

Mannkind Corp. (NASDSQ: MNKD) still slipping today on Pfizer’s insulin scare earlier this month. Pfizer markets an inhaled insulin product, Exubera, that recently studies showed it be connected with lung cancer in its users. Despite the failings of Pfizer’s inhaled insulin product and other developers of similar treatments (including Alkermes above), Mannkind intends to continue developing its similar product, Technosphere. Shares are down almost 7% to $2.33 today on a 52-week range of $2.15 to $15.65. Pfizer (NYSE: PFE) up marginally today to $20.53 on a 52-week range of $20.19 to $27.73.

Generex Biotechnology Corp. (NASDAQ: GNBT) could benefit from Pfizer’s and Mannkind’s struggles with inhaled insulin treatments. Generex’s product Oral-lyn is viewed as a competing oral insulin product that is safe and effective. Shares are up over 2% to $1.18 today on a 52-week range of $0.81 to $2.14.

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) down almost 11% today after they announced that the pre-clinical study of their anti-PS Vascular Targeting Antibodies showed a broad range of potential for cancer treatment at the American Association of Cancer Research annual meeting. Shares are down to $0.44 on a 52-week range of $0.35 to $1.40.

Rachel Lopez
April 14, 2008

Posted on: April 14, 2008 – 12:16 pm in Biotech, , , , , ,

The 52-Week Low Club (BID)(AVR)(MNKD)(GRMN)(SSCC)

Sotheby’s Holdings (BID) Market is turning against companies with rick customers are they become poor. Fallst to $24.37 from 52-week high of $61.40.

Aventine Renewable Energy (AVR) Crop prices go up, ethanol stocks down. Sells off to $4.55 from 52-week high of $20.85.

Mannkind Corp (MNKD) Inhaled insulin products run into FDA approval trouble. Shares drop 60% and hit low of $2.15 from 52-week high of $15.65.

Garmin (GRMN) Still dropping on earnings concerns. Bottoms at $45.38 down from 52-week high of $125.68.

Smurfit-Stone Container (SSCC) Paper companies hit by commodities costs and rising price of oil. Runs down to $6.65 from 52-week high of $14.08.

Douglas A. McIntyre

Posted on: April 9, 2008 – 2:40 pm in HI/LOW, , , , ,

Biotech Monday (CRIS, CGRB, EXEL, MNKD, PDLI, SQNM, TCM)

Curis Inc. (NASDAQ: CRIS) shares down 18% after development partner Wyeth terminated their contract that focused on cancer treatment developments. Shares are down $0.29 to $1.14. The 52 week range is $0.86 to $2.35.

Cougar Biotechnology, Inc. (NASDAQ: CGRB) down 23% to $17.75.

Exelixis (NASDAQ: EXEL) hit a new 5 year low this morning. Its down 7% to $5.38 on a 52 week low of $5.67 to $12.77.  No special reason for the downturn aside from a market wide lack of interest in developmental-stage drugs.

MannKind Corp. (NASDAQ: MNKD) downgrades and fears of ending inhaled insulin development lead to a new all-time low. Shares are down 18% at $4.52 in mid-day trading. The 52 week range is $5.25 to $15.99.

PDL BioPharma (NASDAQ: PDLI) fell another 8% after the recent drops after it canceled its sale last week.  Its shares hit lows of $10.12, another 52-week low.

Sequenom Inc. (NASDAQ: SQNM) down 17% on no new news. Shares are trading at  $5.47  with a  52 week range of $2.93 to $11.63.

Tongjitang Chinese Medicines Co. (NYSE: TCM) shares are up over 33% to $8.83 in mid-day trading on news that the CEO and another board director submitted a proposal to acquire all outstanding shares and take the company private. The 52 week range is $6.57 to $12.88.

Rachel Lopez
March 10, 2008

Posted on: March 10, 2008 – 2:25 pm in Biotech, , , , , , ,

Earlybird Analyst Calls (June 14, 2007)

ACL started as Buy at Jefferies.
AMGN started as Mkt Perform at Rodman & Renshaw.
B started as Outperform at CIBC.
CBB started as Buy at UBS.
CHE started as Buy at Jefferies.
CTL raised to Neutral at UBS.
CYTX started as Mkt Perform at Piper Jaffray.
DJ cut to Reduce at UBS.
EQ raised to Buy at UBS.
ESI cut to Equal Weight at Lehman.
EYE started as Underperform at Jefferies.
GNLB started as Buy at Oppenheimer.
ILMN raised to Outperform at Bear Stearns.
ISIL raised to Buy at B of A.
MFA started as Outperform at JMP Securities.
MNKD started as Buy at B of A.
OPTT started as Outperform at Bear Stearns.
PT raised to Outperform at Credit Suisse.
RACK started as Buy at Merriman Curhan Ford.
RBC started as Sector Perform at CIBC.
SLM cut to Peer Perform at Bear Stearns.
SNY cut to Neutral at HSBC; cut to Neutral at JPMorgan.
THI raised to Outperform at CIBC.
VDSI cut to Hold at Jefferies.
VTIV raised to Strong Buy at First Albany.
WIN started as Neutral at UBS.
ZGEN started as Neutral at Oppenheimer.

Jon C. Ogg
June 14, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 14, 2007 – 6:29 am in Analyst Calls, , , , , , , , , , , , , , , , , , , , , , , , , , ,